Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With Essential Hypertension

NCT00797862 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00797862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00797862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With Essential Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2008
Completion date
November 30, 2010
Enrollment
1,254 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension